ANG Lifesciences India Limited

BSE:540694 Stock Report

Market Cap: ₹583.4m

ANG Lifesciences India Past Earnings Performance

Past criteria checks 0/6

ANG Lifesciences India's earnings have been declining at an average annual rate of -34.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 1.7% per year.

Key information

-34.5%

Earnings growth rate

-33.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate1.7%
Return on equity-20.7%
Net Margin-13.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ANG Lifesciences India makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:540694 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,077-1471780
30 Jun 241,081-1501790
31 Mar 241,461-1011970
31 Dec 231,477-1112140
30 Sep 231,761-692230
30 Jun 232,026-202350
31 Mar 232,199-32430
31 Dec 222,758962410
30 Sep 222,7851362440
30 Jun 223,0812382300
31 Mar 223,5434032150
31 Dec 212,9503641890
30 Sep 212,8363531700
30 Jun 212,3122431540
31 Mar 211,544701400
31 Dec 201,524731350
30 Sep 201,543881130
30 Jun 201,40674960
31 Mar 201,26861830
31 Dec 191,26459750
30 Sep 191,26058620
30 Jun 191,23857650
31 Mar 191,21756720
31 Dec 181,11455670
30 Sep 181,01254620
30 Jun 1888646600
31 Mar 1876037580
31 Dec 1771631530
30 Sep 1767225460
30 Jun 1767527440
31 Mar 1767728430
31 Mar 1655117350
31 Mar 153694240
31 Mar 143462120

Quality Earnings: 540694 is currently unprofitable.

Growing Profit Margin: 540694 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 540694 is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.

Accelerating Growth: Unable to compare 540694's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 540694 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).

Return on Equity

High ROE: 540694 has a negative Return on Equity (-20.7%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:30
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ANG Lifesciences India Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution